Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines

NIH RePORTER · NIH · N44 · $2,199,976 · view on reporter.nih.gov ↗

Abstract

Vaccine design using SARS-CoV-2 spike protein on VLPs which contain GM-CSF and IL-12 (targeting elderly). There is data supporting the premise that including GM-CSF and IL-12 in the VLP can overcome poor immune responses in elderly. Animal testing will begin using VLP with antigen and cytokines, this process will be optimized for GMP and scale-up.

Key facts

NIH application ID: 10259987
Project number: 75N93019C00017-P00003-9999-2
Recipient: METACLIPSE THERAPEUTICS CORPORATION
Principal Investigator: CHRISTOPHER PACK
Activity code: N44
Funding institute: NIH
Fiscal year: 2020
Award amount: $2,199,976
Award type: —
Project period: 2019-08-16 → 2022-08-15